2012-10-10 01:10:34 - New Pharmaceuticals research report from Global Markets Direct is now available from Fast Market Research

Global Markets Direct's, 'Primary Sclerosing Cholangitis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Primary Sclerosing Cholangitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Primary Sclerosing Cholangitis. Primary Sclerosing Cholangitis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468472_primary_sclerosing_cholangitis_pipeli ..


Note*: Certain sections in the

report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Primary Sclerosing Cholangitis.
* A review of the Primary Sclerosing Cholangitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Primary Sclerosing Cholangitis pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Primary Sclerosing Cholangitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Primary Sclerosing Cholangitis pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Report Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Primary Sclerosing Cholangitis Overview
Therapeutics Development
An Overview of Pipeline Products for Primary Sclerosing Cholangitis
Primary Sclerosing Cholangitis Therapeutics under Investigation by Universities/Institutes
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Primary Sclerosing Cholangitis Therapeutics - Products under Investigation by Universities/Institutes
Primary Sclerosing Cholangitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
doconexent - Drug Profile
Product Description
Mechanism of Action
R&D Progress
erlotinib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fenofibrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
metronidazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vancomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
vancomycin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Primary Sclerosing Cholangitis Therapeutics - Discontinued Products
Primary Sclerosing Cholangitis Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Primary Sclerosing Cholangitis, H2 2012
Products under Development for Primary Sclerosing Cholangitis - Comparative Analysis, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Stage and Molecule Type, H2 2012
Primary Sclerosing Cholangitis Therapeutics - Discontinued Products
Primary Sclerosing Cholangitis Therapeutics - Dormant Products

List of Figures
Number of Products under Development for Primary Sclerosing Cholangitis, H2 2012
Products under Development for Primary Sclerosing Cholangitis - Comparative Analysis, H2 2012
Products under Investigation by Universities/Institutes, H2 2012
Mid Clinical Stage Products, H2 2012
Early Clinical Stage Products, H2 2012
Assessment by Monotherapy Products, H2 2012
Assessment by Route of Administration, H2 2012
Assessment by Stage and Route of Administration, H2 2012
Assessment by Molecule Type, H2 2012
Assessment by Stage and Molecule Type, H2 2012

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.